For the year ending 2025-11-30, CCEL made $31,566,321 in revenue. -$2,429,385 in net income. Net profit margin of -7.70%.
| Income Statement | 2025-11-30 | 2024-11-30 | ||
|---|---|---|---|---|
| Revenue | 31,566,321 | 31,918,222 | ||
| Change in fair value of contingent consideration | - | 2,794 | ||
| Impairment of investment | - | -308,000 | ||
| Cost of sales | 7,376,648 | 7,947,752 | ||
| Selling, general and administrative expenses | 18,220,708 | 18,521,218 | ||
| Impairment of investment-Tianhe Stem Cell Biotechnologies Inc | 0 | - | ||
| Impairment of public inventory | 4,358,834 | - | ||
| Research, development and related engineering | 376,263 | 1,242,536 | ||
| Depreciation and amortization | 751,474 | 483,522 | ||
| Total costs and expenses | 31,083,927 | 28,505,822 | ||
| Operating income | 482,394 | 3,480,284 | ||
| (losses) gains on marketable securities | -806,267 | 1,076,051 | ||
| Gain on interest rate swap | 0 | 105,887 | ||
| Other income | 52,976 | 6,583 | ||
| Interest expense | 2,066,256 | 1,864,684 | ||
| Total other (expense) income | -2,819,547 | -676,163 | ||
| (loss) income before income tax expense | -2,337,153 | 2,804,121 | ||
| Income tax expense | 92,232 | 2,402,026 | ||
| Net (loss) income | -2,429,385 | 402,095 | ||
| Basic EPS | -0.3 | 0.05 | ||
| Diluted EPS | -0.3 | 0.05 | ||
| Basic Average Shares | 8,068,777 | 8,130,676 | ||
| Diluted Average Shares | 8,068,777 | 8,212,510 | ||
CRYO CELL INTERNATIONAL INC (CCEL)
CRYO CELL INTERNATIONAL INC (CCEL)